PCIA
HZNP

Prime Capital Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Prime Capital Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,159
Closed -$250K – 998
2023
Q3 		$250K Hold
2,159
– – 0.01% 633
2023
Q2 		$222K Hold
2,159
– – ﹤0.01% 681
2023
Q1 		$236K Buy
+2,159
New +$239K 0.01% 478

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prime Capital Investment Advisors's HZNP Position: Q4 2023 in Review

Prime Capital Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,159 shares — an estimated $250K sold.

Prime Capital Investment Advisors first reported a position in HZNP in Q1 2023 and held it in 3 quarters. The position peaked at $250K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Prime Capital Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 2,159 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $250K.
  • Prime Capital Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 3 quarters.
  • Prime Capital Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $250K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Prime Capital Investment Advisors's 13F filing for Q4 2023, filed 24 Jan 2024.